Lesson plan

Entinostat

Entinostat ( , , ), sold under the brand name Jingzhuda and also known by its developmental code names SNDX-275 and MS-275, is a histone deacetylase (HDAC) inhibitor which is used in the treatment of HER2-negative breast cancer. It is also under development for the treatment of HER2-positive breast cancer and was previously under development for a large number of other cancers. The drug is taken orally.

Back to article

Article summary

Entinostat ( , , ), sold under the brand name Jingzhuda and also known by its developmental code names SNDX-275 and MS-275, is a histone deacetylase (HDAC) inhibitor which is used in the treatment of HER2-negative breast cancer. It is also under development for the treatment of HER2-positive breast cancer and was previously under development for a large number of other cancers. The drug is taken orally.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.